Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Akasi Pharma Logo
Akasi Pharma Growth Score
85
CB Rank
126555
Heat Score
68
Akasi Pharma focuses on developing peptide-based therapeutics aimed at treating peripheral pain conditions.
Founded
obfuscation
PrivatePre-Seed Copenhagen, Hovedstaden, Denmark1-10 akasipharma.com
Health Care
Medical
Therapeutics
Overview

Akasi Pharma
Total Funding
obfuscation
Growth Score
85
Heat Score
68

Total Funding
obfuscation
obfuscation
Pre-Seed raised
obfuscation
Growth Score85
-4 pts
in past quarter
Heat Score 68
-14 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Akasi Pharma

CB Rank
126555
Akasi Pharma focuses on developing peptide-based therapeutics aimed at treating peripheral pain conditions.
Founded
obfuscation
PrivatePre-Seed Copenhagen, Hovedstaden, Denmark1-10 akasipharma.com
Health Care
Medical
Therapeutics

Funding Rounds

Pre-Seed
OBF
in
obfuscation

Details

Operating Status Active
Company Type For Profit
About the Company
Akasi Pharma focuses on developing peptide-based therapeutics aimed at treating peripheral pain conditions, particularly diabetic peripheral neuropathic pain (DPNP). This condition affects a significant number of diabetics, with a lifetime incidence of about 50%, and is notoriously difficult to treat effectively with existing option
Contact Email info@akasipharma.com.
Predictions & Insights

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Runway Speculation

Products & Services

AP-1001
A peptide-based therapeutic candidate targeting somatostatin receptor 4 for treating diabetic peripheral neuropathic pain.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Pre Seed Round - Akasi Pharma Logo
Pre Seed Round - Akasi Pharma
1
obfuscation
BioInnovation Institute Venture LabPre-Seed
obfuscation
Pre Seed Round - Akasi Pharma Logo
Pre Seed Round - Akasi Pharma
1
obfuscation
BioInnovation Institute Venture LabPre-Seed
obfuscation
Pre Seed Round - Akasi Pharma Logo
Pre Seed Round - Akasi Pharma
1
obfuscation
BioInnovation Institute Venture LabPre-Seed
obfuscation
Pre Seed Round - Akasi Pharma Logo
Pre Seed Round - Akasi Pharma
1
obfuscation
BioInnovation Institute Venture LabPre-Seed
obfuscation
Pre Seed Round - Akasi Pharma Logo
Pre Seed Round - Akasi Pharma
1
obfuscation
BioInnovation Institute Venture LabPre-Seed

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Pre Seed Round - Akasi Pharma Logo
Pre Seed Round - Akasi Pharma
1
obfuscation
BioInnovation Institute Venture LabPre-Seed
obfuscation
Pre Seed Round - Akasi Pharma Logo
Pre Seed Round - Akasi Pharma
1
obfuscation
BioInnovation Institute Venture LabPre-Seed
obfuscation
Pre Seed Round - Akasi Pharma Logo
Pre Seed Round - Akasi Pharma
1
obfuscation
BioInnovation Institute Venture LabPre-Seed
obfuscation
Pre Seed Round - Akasi Pharma Logo
Pre Seed Round - Akasi Pharma
1
obfuscation
BioInnovation Institute Venture LabPre-Seed
obfuscation
Pre Seed Round - Akasi Pharma Logo
Pre Seed Round - Akasi Pharma
1
obfuscation
BioInnovation Institute Venture LabPre-Seed

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10
News
Technology
View Tech Report

IT Spend

$30.9KThis year, Akasi Pharma is projected to spend $30.9K on IT, according to Aberdeen.

Active Website Tech Count

6Akasi Pharma is actively using 6 technologies for its website, according to BuiltWith. These include Common Crawl, CommonCrawl Top 50m, and  Apple Mobile Web Clips Icon.
Sub-Organizations
Frequently Asked Questions

Where is Akasi Pharma's headquarters? Akasi Pharma is located in Copenhagen, Hovedstaden, Denmark.Who invested in Akasi Pharma? Akasi Pharma is funded by BioInnovation Institute Venture Lab.When was the last funding round for Akasi Pharma? Akasi Pharma closed its last funding round on
obfuscation
from a Pre-Seed round.Who are Akasi Pharma's competitors? Alternatives and possible competitors to Akasi Pharma may include Eli Lilly, Vertex Pharmaceuticals, and  Scilex Holding Company.How much funding has Akasi Pharma raised to date? Akasi Pharma has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(c22f898 1)
|